Olink Holding AB (publ)

Good day, and thank you for standing by. Welcome to the OLINX Proteomics Q2 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, John Medina, VP of Investor Relations and Capital Markets. Please go ahead.

Thanks, DeeDee, and good morning, everyone. Thank you all for participating in today's conference call. On the call from O-Link, we have John Hymer, Chief Executive Officer, Carl Raymond, President, and Oscar Yeom, Chief Financial Officer. Earlier today, O-Link released financial results for the second quarter ended June 30th, 2023. A copy of the press release and an updated corporate presentation are available on the company's website. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the U.S. federal securities laws, which are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results, or performance are forward-looking statements. Actual results may differ materially from those expressed or implied in the forward-looking statements due to a variety of factors. For a list and description of the risks and uncertainties associated with OLINC's business, please refer to the risk factors section on 2420F, Commission File Number 001-40277, filed with the U.S. Securities and Exchange Commission on March 27, 2023, and in our other filings with the SEC. We urge you to consider these factors, and you should be aware that these statements should be considered estimates only and are not a guarantee of future performance. Also, in our remarks or responses to questions, management may mention some non-IFRS financial measures. Reconciliations of adjusted gross profit and EBITDA, constant currency revenue growth, and certain other non-IFRS financial measures to the most directly comparable IFRS measures are available in the recent earnings press release available on the company's website. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, August 9th, 2023. Oling disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise, except as required by law. And with that, I'll turn the call over to John.

John? Thank you, Jan, and good morning, everyone, and thank you for joining Oling's second quarter 2023 earnings call. I'll begin with highlights of the quarter and recent progress, including our launch of Explore HT and other innovation at Olink. Then I'll turn the call over to Carl to provide more details on our commercial results, Explore HT and Outlook. Following that, Oskar will discuss our financials. Olink saw continued success and business momentum in the second quarter. From high-plex to low-plex, our reach within customer labs around the world continued to expand, driven by strong externalization with both Explore and Signature. We navigated through a challenging external operating environment, which, in combination with our new product launch, pushed our revenue seasonality to be more back-half-weighted, as indicated earlier in the year. Overall, we continued to make expected and solid progress on all major strategic objectives. As we entered the second half of the year, Ohlins' commitment to transformative innovation entered a new chapter with the launch of Explore HT. Explore 1536 and Explore 3072 were both incredible innovations that helped launch the next generation proteomics market, while also laying the foundation for O-Link's leadership. In July, we launched Explore HT to usher in a new era of proteomics, increasing our ambition while doing so and improving upon every major design feature of 3072. We increased the breadth and depth of the library to 5,300 plus validated protein assays, the majority of which belong to O-Link, yielding an 80% increase in unique assays. HT also has sevenfold higher data throughput and a fourfold sample throughput that is scalable from tens to millions of samples. A sixfold reduction in components with a tenfold reduction in boxes and 90% reduction in plastics. significantly reduced cost per data point, including lower sequencing and labor costs, and a simplified workflow, all while maintaining our industry-leading data quality. The power and capability of Explore HT seemed almost unthinkable just a handful of years ago, and we are very proud to offer a product with this level of performance to empower new discoveries in healthcare. Carl will discuss Explore HT and its launch in greater detail. Though I will say that it's been eagerly anticipated by customers, and we believe the initial launch period is going remarkably well. We expected Explore HT will help further cement our market-leading position by demonstrating our commitment to high-quality products and innovation. In software and our data ecosystem, we also made strong progress with Olink Insights significantly expanded its normal ranges resource with data from two large cohorts. This includes data from more than 52,000 UK biobank samples and a subset of data from the China Kadori Biobank, one of the world's largest prospective cohort studies with more than half a million participants. Proteins in health individuals is a critical biological problem. The question, what does normal look like, is a fundamental one that remains largely unanswered, and answers are needed across a myriad of disease states to learn what is not normal. When one considers variables in human populations such as ethnicity, age, and sex, then the diversity of the data pool, the quality of the data measurement, and the competence of the data analysis become critical. Allink Insight enables all of these, and in the process of driving multiple new use cases across customer R&D. As a completely unique data set, we believe O-Link Insights normal ranges resource represents the most extensive collection of proteomics data of its kind. And this is only the beginning. As O-Link Insights users base and data pool both expand over time, its value will increase dramatically for customers within the O-Link ecosystem. and can be further enhanced through advanced data techniques like machine learning and algorithmic approaches. Our mindshare within the scientific community continued to grow during the second quarter as well. Late last year, we reached the milestone of a thousand peer-reviewed publications citing the use of PEA technology, a feat more than five years in the making. Today, less than a year from that impressive achievement, we've exceeded 1,300. and expect to see the rate of strong scientific productivity to continue. Olink and PEA have a growing presence at major medical meetings as well, including the European Society of Human Genetics Conference and the Alzheimer's Association's International Conference in June and July, respectively. We believe Olink's culture of ceaseless innovation has yielded the industry's broadest and most well-positioned product portfolio today, across high- to low-plex, and with end-to-end workflow solutions. The engine of O-Link's success is stronger than ever, and we look to the future with even greater optimism. I'll now turn the call over to Carl to provide more details on our commercial efforts in the second quarter, the Explore HT launch, and what we're seeing in the market. Carl?